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Background: Increased expression of transcriptional coactivator p300 has been observed in a variety of human
cancers. However, the expression status of p300 protein/mRNA in nasopharyngeal carcinoma (NPC) tissues and its
clinicopathologic/prognostic implication are poorly understood.
Methods: In our study, mRNA and protein expression levels of p300 was explored by reverse transcription-
polymerase chain reaction (RT-PCR), Western blotting (WB) and immunohistochemistry (IHC) in nasopharyngeal
mucosal and NPC tissues. The data were analyzed by receiver operating characteristic (ROC) curve analysis,
spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model.
Results: Up-regulated expression of p300 mRNA/p300 protein was detected in NPC tissues by RT-PCR and WB,
when compared to nasopharyngeal mucosal tissues. Based on ROC curve analysis, the cutoff score for p300 high
expression was defined when more than 35% of the tumor cells were positively stained. High expression of p300
was observed in 127/209 (60.7%) of NPCs. In NPCs, high expression of p300 was positively associated with later T
classification, later N classification, distant metastasis and later clinical stage (P< 0.05). In univariate survival analysis,
overexpression of p300 was found to be an indicator of progression-free (P= 0.002) and overall survival (P= 0.001)
in NPCs. More importantly, p300 expression was evaluated as an independent prognostic factor for NPC in
multivariate analysis (P= 0.036).
Conclusions: Our findings support that high expression of p300 protein might be important in conferring a more
aggressive behavior, and is an independent molecular marker for shortened survival time of patients with NPC.
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Nasopharyngeal carcinoma (NPC) is a common malig-
nancy in southern China. The etiologic factors asso-
ciated with NPC are believed to be genetic susceptibility,
EBV infection, and other environmental factors [1-3].
Like other types of human malignant tumors, a multi-
step process consisting of initiation, local progression
and metastasis appears to be dictated by a wide variety
of abnormal genetic changes and this process is involved* Correspondence: zhoutongchong@yahoo.com.cn
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reproduction in any medium, provided the orin the development/progress of NPC [1]. However, the
precise genetic changes that are responsible for NPC
progression are largely unknown. Thus, the identifica-
tion of novel genetic biomarkers is of paramount im-
portance because this would allow early detection of this
cancer, provide new therapeutic targets for treatment
and ultimately improve overall survival for patients with
NPC.
p300, which is known as KAT3B/EP300, is a member
of the histone acetyltransferase family of transcriptional
coactivator. p300 is found to play a variety of roles in
the transcription process and catalyzes histone acetyl-
ation through its histone acetyltransferase activity [4,5].
Transcriptional coactivator p300 is involved in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Correlation between the expression of P300 and










Female 59 25 (42.4%) 34 (57.6%)




≤ 45 89 33 (37.1%) 56 (62.9%)




Type II 54 24 (44.4%) 30 (55.6%)
Type III 155 58 (37.4%) 97 (62.6%)
T classification 0.000
1 26 19 (73.1%) 7 (26.9%)
2 68 37 (54.4%) 31 (45.6%)
3 69 17 (24.6%) 52 (75.4%)
4 46 9 (19.6%) 37 (80.4%)
N classification 0.024
0 40 23 (57.5%) 17 (42.5%)
1 96 34 (35.4%) 62 (64.6%)
2 51 15 (29.4%) 36 (70.6%)
3 22 6 (27.3%) 16 (72.7%)
Distant metastasis 0.021
0 158 69 (43.7%) 89 (56.3%)
1 51 13 (25.5%) 38 (74.5%)
Clinical stage 0.000
I 10 8 (80.0%) 2 (20.0%)
II 55 37 (67.3%) 18 (32.7%)
III 83 23 (27.7%) 60 (72.3%)
IV 61 14 (23.0%) 47 (77.0%)
*Chi-square test; WHO, World Health Organization.
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tion, differentiation, apoptosis, cell-cycle regulation and
DNA damage response [6]. Previous studies also sug-
gested that p300 played a tumor suppressor role in cer-
tain human malignancies, including breast, colorectal
and gastric carcinoma [7,8]. However, recent studies
suggest that p300 is a positive regulator of cancer pro-
gression and related to tumorigenesis of various cancers
[9-11]. Marije et al. indicated that p300 was a cofactor
correlated with p53 accumulation and HIF-1a levels in
invasive breast cancer [12]. It has also been reported that
p300 expression correlates with nuclear alterations of
tumor cells and contributes to the growth of prostate
carcinoma and is a predictor of aggressive features of
this cancer [13,14].
Up to date, the expression dynamics of p300 in NPCs
and its clinicopathologic/prognostic significance has not
been elucidated. In the present study, RT-PCR and
Western blotting, tissue microarray and immunohisto-
chemistry (IHC) were employed to examine the distribu-
tion and frequency of p300 mRNA/protein expression in
our NPC and nasopharyngeal mucosal tissues. The cor-
relations between p300 expression and patient clinico-
pathologic and prognostic significance were assessed to
determine whether the expression of p300 could be a
prognostic biomarker for patients with NPC.
Methods
Patients and tissue specimens
In this study, the paraffin-embedded pathologic spe-
cimens from 209 patients with NPC were obtained
from the archives of Department of Pathology, affilia-
ted Tumor Hospital of Guangzhou Medical College,
Guangzhou, China, between February 2004 and July
2007. These NPC cases included 150 (71.8%) men and
59 (28.2%) women, with mean age of 45 years. Average
follow-up time was 72.8 months (range, 3.0 to
233 months). Clinicopathologic characteristics for these
patients including age, sex, Histological classification, T
classification, N classification, distant metastasis, Clinical
stage were described in Table 1. For the use of these
clinical materials for research purposes, prior patient’s
consent and approval from the Institute Research Ethics
Committee were obtained. The disease stages of all the
patients were classified or reclassified according to the
1992 nasopharyngeal carcinoma staging system of
China.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from 4 pairs of NPC and
nonneoplastic nasopharyngeal mucosal tissues using
TRIZOL reagent (Invitrogen, Carlsbad, CA). RNA
was reverse-transcribed using SuperScript First Strand
cDNA System (Invitrogen, Carlsbad, CA) accordingto the manufacture’s instructions. The following pri-
mers were used for amplification of p300: sense pri-
mer 5'-AAACCCACCAGATGAGGA C-3', antisense
primer, 5'-TATGCACTAGATGGCTCCGCAG-3'. The
primers used for beta actin (internal control) were
5'-CGAAACTACCTTCAACTCCATCA-3' and 5'-
CGGACTCGTCATACTCCTGCT-3'. The PCR pro-
ducts were analyzed by agarose gel electrophoresis
and confirmed by appropriate size and/or sequencing.
Western blotting analysis
Equal amounts of tissue lysates were separated by SDS-
PAGE and electrophoretically transferred to a polyvinyli-
dene difluoride membrane. Membranes were blocked in
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probed with p300 antibody (Abcam, Cambridge, MA) at
4°C overnight. After washing, the membranes were incu-
bated with horseradish peroxidase-conjugated goat anti-
mouse secondary antibodies (Jackson ImmunoResearch
Laboratories) and visualized using the enhanced chemi-
luminescence kit (Forevergen Biosciences, China). The
procedures followed were conducted in accordance with
the manufacturer’s instructions.
Tissue microarray (TMA) construction
Tissue microarray was constructed as the method
described previously [15]. Briefly, tissues samples from
250 NPC and 40 nasopharyngitis cases were collected,
fixed in formalin and embedded in paraffin. H&E-
stained slides were reviewed by a senior pathologist to
determine and mark out representative tumor areas.
Duplicates of 0.6 mm diameter cylinders were punched
from representative tumor areas of individual donor tis-
sue block and re-embedded into a recipient paraffin
block at defined position, using a tissue arraying instru-
ment (Beecher Instruments, Silver Spring, MD). After
the exclusion of cores with inadequate tissue after sec-
tioning and tissue transfer, the final IHC analyses
included 209 NPC and 30 nasopharyngitis cases.
Immunohistochemistry (IHC)
The TMA slides were dried overnight at 60°C, deparaffi-
nized in xylene, rehydrated through graded alcohol,
immersed in 3% hydrogen peroxide for 20 minutes to
block endogenous peroxidase activity, and antigen-
retrieved by pressure cooking for 3 minutes in ethylene-
diamine tetraacetic acid (EDTA) buffer (pH= 8.0). Then
the slides were preincubated with 10% normal goat
serum at room temperature for 30 minutes to reduce
nonspecific reaction. Subsequently, the slides were incu-
bated with mouse monoclonal anti-p300 (Abcam,
Cambridge, MA) at a concentration of 3 ng/ml for 2
hours at room temperature. The slides were sequentially
incubated with a secondary antibody (Envision; Dako,
Glostrup, Denmark) for 1 hour at room temperature,
and stained with DAB (3,3-diaminobenzidine). Finally,
the sections were counterstained with Mayer’s
hematoxylin, dehydrated, and mounted. A negative con-
trol was obtained by replacing the primary antibody with
a normal mouse IgG.
IHC evaluation
Nuclear staining for p300 protein was reported in semi-
quantitative method by assessing the number of positive
cancer and mucosal cells over the total number of can-
cer and mucosal cells, respectively. Scores were assigned
by using 5% increments (0%, 5%, 10%-100%). Expression
for p300 was scored by 3 independent pathologistsblinded to clinicopathological data. Their conclusions
were in complete agreement in 78.5% of the cases, which
identified this scoring method as highly reproducible.
Selection of cutpoint score
ROC curve analysis was employed to determine cutoff
score for tumor “high expression” by using the 0, 1-
criterion [16]. For the p300 score, the sensitivity and
specificity of each outcome under study was plotted,
thus generating various ROC curves. The score was
selected as the cutoff value, which was closest to the
point with both maximum sensitivity and specificity.
Tumors designated as “low expression” for p300 were
those with scores below or equal to the cutoff value,
while “high expression” tumors were those with scores
above the value. For ROC curve analysis, the clinico-
pathologic features were dichotomized: T classification
(T1-T2 versus T3-T4), N classification (N0-N1 versus
N2-N3), distant metastasis (M0 versus M1), clinical
stage (I-II versus III-IV), cancer progression (Yes ver-
sus No) and survival status (death due to NPC versus
censored).
Statistical analysis
Statistical analysis was performed by using the SPSS stat-
istical software package (standard version 13.0; SPSS,
Chicago, IL). ROC curve analysis was utilized to define
the cutoff score for high expression of p300. The correl-
ation between p300 expression and clinicopathological
characteristics of NPC patients was evaluated by χ2-test.
Univariate and multivariate survival analyses were per-
formed using the log-rank test and Cox proportional
hazards regression model, respectively. Survival curves
were obtained with the Kaplan-Meier method. Differ-
ences were considered significant if the P-value from a
two-tailed test was <0.05.
Results
The expression of p300 in NPCs and nonneoplastic
mucosal tissues by RT-PCR and western blotting
In the present study, the levels of expression of p300
mRNA and p300 protein were examined by RT-PCR and
Western blotting, respectively, in 4 pairs of fresh NPC
and nonneoplastic mucosal tissues. Our results revealed
that all NPCs were examined as having up-regulated
p300 protein expression (Figure 1A), when compared
with nonneoplastic mucosal tissues. Up-regulated ex-
pression of p300 mRNA also was observed in all NPCs
(Figure 1B).
The expression patterns of p300 in NPCs and
nonneoplastic mucosal tissues by IHC
For p300 IHC staining in NPCs and nonneoplastic mu-
cosal tissues, immunoreactivity was primarily seen in the
Figure 1 The mRNA and protein expression of p300 in NPCs and nonneoplastic mucosal tissues. A. Up-regulated expression of p300
mRNA was examined by RT-PCR in 4/4 NPC cases, when compared with n nonneoplastic mucosal tissues. B. Up-regulated expression of p300
protein was detected by Western blotting in 4/4 HCC cases, when compared with nonneoplastic mucosal tissues. C. High expression of p300 was
observed in a NPC, in which more than 90% tumor cells revealed positive immunostaining of p300 in nuclei (upper panel, ×100). D. A NPC case
demonstrated low expression of p300, in which less than 5% of tumor cells showed immunoreactivity of p300 protein in nuclei (upper panel,
×100). E. The nonneoplastic mucosal tissue showed nearly negative expression of p300 protein (upper panel, ×100). The lower panels indicated
the higher magnification (×400) from the area of the box in C., D., and E., respectively.
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A negative control demonstrating the specificity of
the signal was shown in a breast cancer with nega-
tive expression of p300 (Additional file 1: Figure S1).
p300 expression could be assessed informatively in
209 NPCs by the TMA constructed previously. The
non-informative TMA samples included samples with
too few tumor cells (<300 cells per case) and lost
samples. Staining intensity of p300 in NPC ranged
from 0% to 100% (Figure 1C-1E). According to ROC
curve analysis, expression percentage for p300 above
the cutoff value 35% was defined as high expression,
while below or equal to the cutoff value was consid-
ered as low expression. In this study, high expression
of p300 could be detected in 127/209 (60.7%) of
NPCs. and 8/30 (26.7%) of nonneoplastic mucosal
tissues, respectively (P< 0.05, Fisher’s exact test).
Selection of cutoff scores for p300 high expression
The ROC curves for each clinicopathological param-
eter (Figure 2) clearly show the point on the curve
closest to (0.0, 1.0) which maximizes both sensitivityand specificity for the outcome as described in previ-
ous study [17]. Tumors with scores above the
obtained cutoff value were considered as high p300
expression leading to the greatest number of tumors
classified based on clinical outcome presence or ab-
sence. Cutoff score for p300 high expression was
determined to be more than 50% carcinoma cells
staining.
Association of p300 expression with NPC patients’
clinicopathological parameters
The high or low expression rates of p300 in NPCs with
respect to several standard clinicopathologic features are
presented in Table 1. The high p300 expression rate was
higher in patients with later T classification (P< 0.0001),
later N classification (P = 0.024), distant metasta-
sis (P = 0.021), and later clinical stage (P< 0.0001,
Table 1). There was no significant correlation be-
tween p300 expression and other clinicopatholo-
gic parameters, such as patient age (≤45 years
vs >45 years), sex, histological classification (WHO)
(P> 0.05, Table 1).
Figure 2 ROC curve analysis was used to determine the cut-off score for positive expression of p300 protein. The sensitivity and
specificity for each outcome were plotted: (A.) T classification (P= 0.001); (B.) N classification (P< 0.001); (C.) Clinical stage (P< 0.001); (D.) Survival
status (P< 0.001); (E.) Distant metastasis (P= 0.007); (F.) Cancer progression (P= 0.008).
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expression, and NPC patients’ survival: Univariate survival
analysis
In order to confirm the representativeness of the NPCs in
our study, we analyzed established prognostic factors of
patients’ survival. Kaplan-Meier analysis demonstrated a
significant impact of well-known clinicopathologic prog-
nostic parameters, such as T classification (P=0.012), N
classification (P< 0.0001), distant metastasis (P< 0.0001),
and clinical stage (P< 0.0001) on patients’ survival
(Table 2). Assessment of survival in total NPCs revealed
that high expression of p300 was correlated with overall
survival (P= 0.001) of NPC patients (Table 2, Figure 3A).
In addition, high expression of p300 in NPCs was evalu-
ated to correlate closely with poor progression-free sur-
vival (P= 0.002, Table 2, Figure 3B).
Independent prognostic factors of NPC: Multivariate Cox
regression analysis
Since features observed to have a prognostic influence by
univariate analysis may covariate, p300 expression and
those clinicopathologic variables that were significant inunivariate analysis (i.e., T classification, N classification, dis-
tant metastasis and clinical stage) were further examined in
multivariate analysis. Our results showed that high expres-
sion of p300 was an independent prognostic factor for poor
patient overall survival (hazard ratio, 1.830; 95%CI, 1.040-
3.220, P=0.036; Table 2). Of the other parameters, Distant
metastasis (P=0.006) was evaluated as well independent
prognostic factors for patients’ overall survival.
Discussion
The outcomes of NPC patient with same stage following
radiotherapy are different substantially and such large dis-
crepancy has not been investigated. Thus, there is a need for
new objective strategies that can effectively distinguish
between patients with favorable and unfavorable prognosis
for NPC. Molecular biomarkers in conjunction with stand-
ard TNM strategy, certainly has the potential to more effect-
ively ascertain patient prognosis and develop appropriate
therapeutic regimens. Although NPC has been widely stud-
ied, the search and identification of promising molecular
and/or genetic alterations in NPC cells that have clinical/
prognostic significance remains substantially limited.
Table 2 Univariate and multivariate analysis of different prognostic variables in 209 patients with nasopharyngeal
carcinoma
Variable Univariate analysis1 Multivariate analysis2




Age at surgery (years) 0.237
≤ 45 89 119.4
> 45 120 162.9
Histological classification (WHO) 0.059
Type II 54 180.5
Type III 155 120.3
T classification 0.012 0.829 (0.444-1.549) 0.557
T1-T2 94 158.5
T3-T4 115 142.5
N classification 0.000 1.368 (0.815-2.297) 0.235
N0-N1 136 172.2
N2-N3 73 79.1
Distant metastasis 0.000 2.000 (1.217-3.289) 0.006
0 158 171.2
1 51 69.3
Clinical stage 0.000 1.836 (0.739-4.563) 0.191
I-II 65 175.7
III -IV 144 140.0
P300 expression 0.000 1.830 (1.040-3.220) 0.036
Low 82 172.7
High 127 135.3
1Log-rank test; 2Cox regression model; CI, confidence interval; WHO, World Health Organization.
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assays through its correlation with the transcription fac-
tor CREB [18]. Transcriptional coactivator p300 has the
potential to participate in a variety of cellular functions,
including cell proliferation and differentiation, senes-
cence and apoptosis [6]. Recently, several study docu-
mented an involvement of p300 in oncogenic processes,
such as lung, colon, prostate, breast cancer and leukemia
[13,19-22]. In addition, mutation in p300 gene, accom-
panied by loss of the other allele, has been observed in
certain types of tumors, including colorectal, gastric and
breast cancer [7,8]. Up to the present, there is still no
study that explored the status of p300 and its potential
impact in NPC tumorigenesis.
In the present study, we examined the expression
levels of p300 mRNA and p300 protein in NPC tissues
and non-nasopharyngeal carcinoma tissues, firstly by
RT-PCR and Western blotting. Our results established
that up-regulated expression of p300 mRNA and p300protein was shown in the NPCs, when compared to
non-nasopharyngeal carcinoma tissues. Subsequently,
the expression dynamics of p300 protein was investi-
gated by IHC, using a TMA containing NPC tissues and
non-nasopharyngeal carcinoma tissues. Our IHC results
demonstrated that high expression of p300 was more
frequently observed in NPC tissues than in the non-
nasopharyngeal carcinoma tissues. The expression of
p300 in non-nasopharyngeal carcinoma tissue was either
absent or at low levels. In contrast, in large number of
our NPC tissues, high expression of p300 was frequently
observed. These findings suggest the possibility that up-
regulated expression of p300 may provide a selective ad-
vantage in NPC tumorigenic processes.
To assess the significance of p300 protein in NPCs
and avoid predetermined arbitrary cutpoint, ROC curve
analysis was utilized to determine cut-off score for p300
high expression as described previously [16]. Further
correlation analysis showed that high expression of p300
Figure 3 Kaplan–Meier survival analysis according to p300 expression in 209 patients with nasopharyngeal carcinomas (log-rank test).
A. Relationship of p300 expression to overall survival: low expression, n = 82; high expression, n = 127. B. Relationship of p300 expression to
progression-free survival: low expression, n = 82; high expression, n = 127.
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cation, distant metastasis, and clinical stage. More im-
portantly, high expression of p300 was a strong and
independent predictor of shortened overall survival as
evidenced by univariate and multivariate analysis. Our
findings in this study suggest that expression of p300 in
NPC may facilitate an increased malignant feature and/
or worse prognosis of this tumor. Thus, the examination
of p300 expression by IHC could be used as an add-
itional tool in identifying those patients at risk of NPC
progression; p300 expression analysis may also be useful
in optimizing individual NPC therapy management:
favoring a more aggressive regimen in tumors with a
high expression of p300.
Several characteristics of p300 suggested that the pro-
tein might serve as a tumor suppressor; however, some
studies indicated an important role of p300 protein in
oncogenic processes [6,23]. In prostate cancer, p300 ex-
pression was shown to be linked to proliferation and was
found predictive for progression of this cancer [14]. In
colon carcinoma, overexpression of p300 was indicative
of poor prognosis [19]. Moreover, p300 mRNA levels
were observed to correlate with lymph node status in
breast cancer [22]. However, p300 protein levels did not
show significant correlations with tumor grade or nodal
positivity in other study [24,25]. In the present study, we
observed that high expression of p300 was associated
with an aggressive feature of NPC and was a strong and
independent predictor of shorter cancer-specific survival.
Considering that the mechanism by which coactivator
p300 promotes gene transcription may vary among gene
targets, it is not very hard for us to understand that the
function of p300 and its underling mechanism(s) to im-
pact cancer progression may lead to this discrepancy, our
findings suggest a potential important role of p300 in the
control of NPC cell proliferation, an activity that mightbe responsible, at least in part, for NPC tumorigenesis
and/or progression.
Conclusions
Our findings provide a basis for the concept that high
expression of p300 may play an important role in the ac-
quisition of an aggressive phenotype in NPC, suggesting
that the expression of p300, as examined by IHC, will be
a promising independent biomarker for shortened sur-
vival time of NPC patients.
Additional file
Additional file 1 Figure S1. Negative control of p300 IHC.
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